Market Access NICE and the controversy over a ‘clinically distinct disease... Payers worldwide are struggling with a new generation of precision medicines that come with a hefty price tag.
News Roivant's new ''vant' emerges to advance Bayer lung drug Roivant's latest biotech company launch – Pulmovant – has made its debut with a plan to develop a respiratory drug licensed from Bayer in a deal worth up to $294 million.
Sales & Marketing Sponsored How doctors are interacting with content in 10 data trends It will come as no surprise to anyone in the healthcare space that doctors today are under an inordinate amount of pressure.
